Focused ultrasound with pembrolizumab for recurrent glioblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of focused ultrasound and the immunotherapy drug pembrolizumab for people whose glioblastoma has returned after standard treatment. The ultrasound may help the drug work better by temporarily opening the blood-brain barrier.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a type of brain tumor called glioblastoma (grade 4 IDH-wildtype).
- You have already had standard treatments including surgery, chemotherapy (temozolomide), and radiation.
- You have had surgery again because the tumor came back.
- Your tumor cells have a specific DNA repair problem called mismatch repair deficiency.
- The area where the ultrasound will be focused is at least 30 mm from the inside of your skull.
- You are 18 or older, and your overall health status is good (KPS score above 70).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a focused ultrasound system (NaviFUS) to the drug bevacizumab can help people whose glioblastoma has come back. The treatment aims to deliver the drug more precisely to the brain tumor and potentially improve outcomes.
This trial tests a device that opens the blood-brain barrier using ultrasound, allowing chemotherapy to reach the brain tumor better. It compares this approach to standard chemotherapy for people whose glioblastoma has returned.
This study tests whether adding focused ultrasound to the standard drug Avastin (bevacizumab) can help treat recurrent glioblastoma. The ultrasound may help more of the drug reach the tumor.
This trial tests a new way to take a tiny tissue sample from a suspected glioblastoma using ultrasound, to improve noninvasive detection. You may be able to get this targeted sample while you’re already planning surgery for tumor removal.
This trial tests whether adding the Optune device (a wearable electric field therapy) to standard chemotherapy (temozolomide) and the immunotherapy drug pembrolizumab can help people with newly diagnosed glioblastoma live longer. You may be able to join if you've completed initial radiation and chemo, and have not received certain immunotherapies before.
This trial tests a new approach that uses a light-sensitive drug and low-intensity ultrasound to make standard chemotherapy more effective for glioblastoma. If you have completed initial treatment with radiation and temozolomide without the tumor growing, you may be eligible.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.